Press Releases

Press Releases

Octagos Health announces strategic investments in product, AI and talent

Following its recent $43 million Series B funding, the company is expanding its data integration capabilities to include a broader range of devices, including wearables, heart failure monitoring, and remote patient monitoring.

Elutia announces first patient implant of EluPro, the world’s first drug-eluting bioenvelope for cardiac pacemakers and neurostimulators

The procedure was performed in Greenville, North Carolina.

2023 Hearst Health Prize - AI for Incidental CAC

Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.

DASI Simulations' PrecisionTAVI gets CMS Hospital Outpatient Billing Code

Predictive model generation for pre-planning a cardiac procedure now reimbursable by Medicare at approximately $1,000 per model

 

Echo IQ's breakthrough research on cardiovascular health continues with unveiling of AI-driven aortic stenosis and mitral regurgitation detection results at ESC 2023 Congress

Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.

 

Keystone Perfusion Services, PC recognized for life-saving contribution during COVID-19 pandemic, secures fifth consecutive year on Inc. 5000 list
| Submitted by: Keystone Perfusion Services, PC

The company's multifaceted healthcare staffing solutions play a pivotal role in transforming patient care and elevating industry standards.

 

Corazon and the Society for Cardiovascular Angiography and Interventions announce partnership

The agreement formally endorses Corazon’s cardiovascular accreditation.

Arineta announces SpotLight Duo, the world’s first dedicated cardiovascular and thoracic CT system

Arineta Cardio Imaging is excited to announce the FDA 510(k) clearance of the SpotLight and SpotLight Duo family of cardiovascular CT scanners.

Study Confirms Ultromics’ AI Can Improve HFpEF Detection Using a Single Echocardiogram View

 

Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately. 

 

Cassling connects cardiologists with revolutionary AI software

The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.

 

DASI Simulation’s Precision TAVI earns FDA clearance
| Submitted by: DASI Simulations

Precision TAVI is the first FDA-approved predictive modeling tool for medical teams planning TAVR procedures.

 

 

RecoverRite®, American College of Cardiology Collaborate to Change the Face of Cardiovascular Patient Education

RecoverRite’s Online Heart Learning Center to feature ACC’s CardioSmart patient tools and resources.

Study shows PulseAI’s deep learning algorithm outperforms the Apple Watch ECG algorithm in detecting atrial fibrillation

PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.

 

$20M gift announced by the Rooney Foundation in support of enhanced cardiac care at NCH

NAPLES, Fla. – February 20, 2023   The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney.  In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”

NCH announces second historic gift in as many weeks totaling a record $40M in support of enhanced care

NAPLES, Fla. – February 21, 2023   On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard.  This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida.  Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”

Patient Image Exchange puts patients 'in the driver’s seat'

When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.

 

Ancora Heart appoints David J. Tucker as chief financial officer

Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.

Geneticure presents data successfully identifying responders and non-responders to renal denervation using genetic screening

Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.

Cardiac Insight Comments on CMS Announcement of National Payment Rates for Long-Term Continuous ECG (LT-ECG) Monitoring in 2023

Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System

Medtronic Reports Third Quarter Financial Results

DUBLIN — February 19, 2019 — Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2019, which ended January 25, 2019.

Keck Medicine of USC Announces Acquisition of Los Angeles Cardiology Associates

Newswise — LOS ANGELES – Keck Medicine of USC announces the acquisition of Los Angeles Cardiology Associates, a cardiovascular care group with eight locations across the Los Angeles region. This acquisition, effective Feb. 24, 2019, expands the cardiovascular care provided by Keck Medicine of USC and adds 11 physicians to the institution’s roster of faculty cardiologists.

Medtronic Receives FDA Approval on Expanded Indication for Pipeline Flex Embolization Device

DUBLIN — February 7, 2019 — Medtronic plc (NYSE:MDT) announced today that it has received U.S. Food and Drug Administration (FDA) approval on an expanded indication for its Pipeline(TM) Flex embolization device.

American College of Cardiology Acquires MedAxiom

WASHINGTON (Feb 04, 2019) — The American College of Cardiology Foundation has acquired MedAxiom, a cardiovascular membership, services and consulting firm, adding the company’s recognized leadership in cardiovascular operations, performance improvement, and business acumen to ACC’s world class science, education, registry, quality improvement and advocacy work.

First Atrial Fibrillation Patient Treated In Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation Catheter

IRVINE, Calif., Feb. 4, 2019 — Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study which evaluates the company's QDOT MICRO Radiofrequency (RF) Ablation Catheter used for the treatment of symptomatic drug-refractory paroxysmal atrial fibrillation (AF).

Medtronic Valiant(TM) Captivia(TM) Demonstrates Durability, Safety, and Efficacy at Five Years in Transection Patients

DUBLIN and SAN DIEGO - January 30, 2019 - Medtronic plc (NYSE:MDT) today announced new data supporting the long-term durability, safety, and efficacy of the Valiant(TM) Captivia(TM) thoracic stent graft system for the treatment of blunt thoracic aortic injury (BTAI). The presentation by Himanshu J. Patel, M.D., University of Michigan Department of Cardiac Surgery at The Society of Thoracic Surgeons Annual Meeting, was the first and only five-year industry-issued dataset ever reported for patients with aortic transections undergoing thoracic endovascular aortic repair (TEVAR). 

Impella Connect Achieves Regulatory Milestone

DANVERS, Mass. — Abiomed (NASDAQ:ABMD) has achieved CE Mark for Impella Connect, the first-of-its kind cloud-based technology that enables secure, real-time, remote viewing of the Impella console for physicians and hospital staff from anywhere with Internet connectivity. European CE Mark adds to Impella Connect’s previous U.S. FDA PMA approval.

AF Symposium 2019: Acutus AcQMap Imaging System Helps Physicians Eliminate Arrhythmia with a Single Ablation

CARLSBAD, Calif., Jan. 28, 2019 — Acutus Medical today announced 12-month data from the UNCOVER-AF trial investigating the use of the AcQMap advanced cardiac imaging and mapping visualization system in persistent atrial fibrillation (AF) ablation procedures.

Medtronic to Acquire EPIX Therapeutics, Expanding Its Cardiac Ablation Portfolio

DUBLIN — January 24, 2019 — Medtronic plc (NYSE: MDT) today announced that it has entered into a definitive agreement to acquire EPIX Therapeutics, Inc. (EPIX), a privately-held medical device company that designs and manufactures a novel, catheter-based, temperature-controlled cardiac ablation system for the treatment of patients with cardiac arrhythmias (irregular heartbeats), including atrial fibrillation (AF).

New data from the IMPERIAL clinical program demonstrates ELUVIA more effective in diabetic patients

LEIPZIG and MARLBOROUGH, Mass. (January 22, 2019) — Boston Scientific (NYSE: BSX) today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically significant lower rates of target lesion revascularization (TLR) and stent thrombosis when compared to those treated with the Zilver® PTX® Drug-Eluting Peripheral Stent. 

VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes in Patients with Deep Venous Blockages

LEIPZIG, Germany and MARLBOROUGH, Mass., Jan. 22, 2019 — Today, Boston Scientific (NYSE: BSX) announced positive 12-month data demonstrating that patients who were treated with the VICI VENOUS STENT® System for iliac and femoral vein obstructions exhibited a high rate of patent, or open, target lesions.

RFPI receives FDA clearance to market iCertainty blood flow imaging device

GREENVILLE, N.C. — RFPi Inc. has received 510(k) clearance from the U.S. Food and Drug Administration to begin marketing for use by surgeons in open surgery its iCertainty™ blood flow and perfusion imaging medical device.

UC awarded $3.2 million to study stroke recurrence risk

Researchers at the University of Cincinnati (UC) have received a $3.2 million grant from the National Institute of Neurological Diseases (NINDS) to study the use of neuroimaging to pinpoint the risk factors of stroke recurrence.

University of Miami Health System Welcomes Internationally Renowned Cardiac Surgeon, Joseph Lamelas, MD

Joseph Lamelas, M.D., an internationally recognized expert cardiac surgeon who helped pioneer minimally invasive approaches to cardiac surgery, has joined the University of Miami Health System as chief of cardiothoracic surgery and professor of surgery within the Miller School of Medicine.

Retia Medical Receives U.S. Food and Drug Administration Clearance for its Innovative Argos Cardiac Output Patient Monitor

VALHALLA, N.Y., Dec. 17, 2018 — Retia Medical, LLC, a medical device company focused on advancing the quality and clinical use of hemodynamic monitoring, today announced that its Argos Cardiac Output (CO) Monitor has received U.S. Food and Drug Administration 510k clearance and is now available for sale in the United States.

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 13, 2018 — The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary approach at cardiology clinics across the U.S.

Medtronic Named One of America's Best Corporate Citizens in 2018 by Forbes Magazine

DUBLIN — December 10, 2018 — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has been named one of America's Most JUST Companies in 2018, according to Forbes magazine and JUST Capital, a nonprofit that ranks publicly-traded corporations on the issues Americans care about most.

Contego Medical Receives 510(k) Clearance for the Vanguard IEP Peripheral Angioplasty System with Integrated Embolic Protection

RALEIGH, N.C., Dec. 7, 2018—Contego Medical announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Vanguard IEP® Peripheral Balloon Angioplasty System with Integrated Embolic Protection.

HeartFlow Initiates PRECISE Randomized Clinical Trial

REDWOOD CITY, Calif.—HeartFlow, Inc. today announced the start of the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) trial. The first patient was enrolled by Michael C. Turner, M.D., at Imperial Health Cardiovascular Specialists in Lake Charles, LA.

Arizona patients successfully receive the world’s first bioconvertible IVC filter commercially offered in US

BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter.

Medtronic Announces First Patient Treated in TERMINATE AF Clinical Trial

DUBLIN — December 3, 2018 — Medtronic plc (NYSE:MDT) today announced the first patient treated in the TERMINATE AF trial, a multi-center study evaluating two surgical ablation devices — the Cardioblate(TM) Irrigated RF (IRF) System and the CryoFlex(TM) Surgical Ablation System — for the treatment of non-paroxysmal (persistent or longstanding persistent) atrial fibrillation (AF) in patients undergoing open-heart surgical procedures.